207 related articles for article (PubMed ID: 31238119)
1. Does linezolid have a role in shortening treatment of tuberculosis?
Yew WW; Chan DP; Chang KC
Clin Microbiol Infect; 2019 Sep; 25(9):1060-1062. PubMed ID: 31238119
[No Abstract] [Full Text] [Related]
2. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
Wasserman S; Meintjes G; Maartens G
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
[TBL] [Abstract][Full Text] [Related]
3. BPaL approved for multidrug-resistant tuberculosis.
Burki T
Lancet Infect Dis; 2019 Oct; 19(10):1063-1064. PubMed ID: 31559963
[No Abstract] [Full Text] [Related]
4. A Faropenem, Linezolid, and Moxifloxacin Regimen for Both Drug-Susceptible and Multidrug-Resistant Tuberculosis in Children: FLAME Path on the Milky Way.
Deshpande D; Srivastava S; Nuermberger E; Pasipanodya JG; Swaminathan S; Gumbo T
Clin Infect Dis; 2016 Nov; 63(suppl 3):S95-S101. PubMed ID: 27742640
[TBL] [Abstract][Full Text] [Related]
5. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
6. Linezolid in children with drug resistant tuberculosis.
Shah I; Dey A; Shetty NS
Infect Dis (Lond); 2018; 50(11-12):868-870. PubMed ID: 30296864
[No Abstract] [Full Text] [Related]
7. [The analysis of clinical data about the treatment of linezolid against tuberculosis].
Nie WJ; Chu NH
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Aug; 36(8):601-3. PubMed ID: 24252739
[No Abstract] [Full Text] [Related]
8. Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis.
Almeida D; Li S-Y; Lee J; Hafkin B; Mdluli K; Fotouhi N; Nuermberger EL
Antimicrob Agents Chemother; 2023 Dec; 67(12):e0078923. PubMed ID: 37966090
[TBL] [Abstract][Full Text] [Related]
9.
Shoen C; DeStefano M; Hafkin B; Cynamon M
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784848
[TBL] [Abstract][Full Text] [Related]
10. Linezolid: a Promising Agent for the Treatment of Multiple and Extensively Drug-Resistant Tuberculosis.
Fermeli DD; Marantos TD; Liarakos AD; Panayiotakopoulos GD; Dedes VK; Panoutsopoulos GI
Folia Med (Plovdiv); 2020 Sep; 62(3):444-452. PubMed ID: 33009738
[TBL] [Abstract][Full Text] [Related]
11. Linezolid in the treatment of drug-resistant tuberculosis: the way forward?
Yew WW; Lange C
Int J Tuberc Lung Dis; 2014 Jun; 18(6):631-2. PubMed ID: 24903928
[No Abstract] [Full Text] [Related]
12. Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
Zimenkov DV; Nosova EY; Kulagina EV; Antonova OV; Arslanbaeva LR; Isakova AI; Krylova LY; Peretokina IV; Makarova MV; Safonova SG; Borisov SE; Gryadunov DA
J Antimicrob Chemother; 2017 Jul; 72(7):1901-1906. PubMed ID: 28387862
[TBL] [Abstract][Full Text] [Related]
13. Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.
Zhang S; Chen J; Cui P; Shi W; Shi X; Niu H; Chan D; Yew WW; Zhang W; Zhang Y
Antimicrob Agents Chemother; 2016 Apr; 60(4):2542-4. PubMed ID: 26810645
[TBL] [Abstract][Full Text] [Related]
14. [Severe linezolid-induced toxic optic neuropathy].
Xerri O; Lemaire B; Nasser G; Rousseau-Huvey B; Labetoulle M; Rousseau A
J Fr Ophtalmol; 2015 Mar; 38(3):e55-8. PubMed ID: 25637235
[No Abstract] [Full Text] [Related]
15. [Effect of linezolid in combination with isoniazid and rifampicin against multidrug resistant Mycobacterium tuberculosis clinical isolates].
Coban AY; Bilgin K; Uzun M; Durupinar B
Mikrobiyol Bul; 2009 Apr; 43(2):293-7. PubMed ID: 19621615
[TBL] [Abstract][Full Text] [Related]
16. Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?
Chang KC; Yew WW; Cheung SW; Leung CC; Tam CM; Chau CH; Wen PK; Chan RC
Antimicrob Agents Chemother; 2013 Jul; 57(7):3445-9. PubMed ID: 23650165
[TBL] [Abstract][Full Text] [Related]
17. In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis complex isolated in Taiwan over 10 years.
Huang TS; Liu YC; Sy CL; Chen YS; Tu HZ; Chen BC
Antimicrob Agents Chemother; 2008 Jun; 52(6):2226-7. PubMed ID: 18391030
[TBL] [Abstract][Full Text] [Related]
18. Delamanid, Bedaquiline, and Linezolid Minimum Inhibitory Concentration Distributions and Resistance-related Gene Mutations in Multidrug-resistant and Extensively Drug-resistant Tuberculosis in Korea.
Yang JS; Kim KJ; Choi H; Lee SH
Ann Lab Med; 2018 Nov; 38(6):563-568. PubMed ID: 30027700
[TBL] [Abstract][Full Text] [Related]
19. Antimycobacterial activity of linezolid against multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis in Iran.
Kazemian H; Haeili M; Kardan Yamchi J; Rezaei F; Gizaw Feyisa S; Zahednamazi F; Mohajeri P; Zaker Bostanabd S; Hashemi Shahraki A; Imani Fooladi AA; Feizabadi MM
Int J Antimicrob Agents; 2015 Jun; 45(6):668-70. PubMed ID: 25795315
[No Abstract] [Full Text] [Related]
20. Infectious disease. Approval of novel TB drug celebrated--with restraint.
Cohen J
Science; 2013 Jan; 339(6116):130. PubMed ID: 23307714
[No Abstract] [Full Text] [Related]
[Next] [New Search]
